Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Racura Oncology Ltd has applied for quotation on the ASX of 29,217 new ordinary fully paid shares, effective 8 January 2026, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities reflects ongoing capital management and may slightly broaden the company’s free float and shareholder base without materially altering its overall capital structure.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd (ASX: RAC) is a listed biotechnology company focused on developing oncology therapies, with its primary activities centred on cancer-related drug development and associated clinical programs for the healthcare and life sciences market.
Average Trading Volume: 313,299
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$493.7M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.